Thermo Fisher Scientific Launches RNAi Services Laboratory Supporting Researchers in Drug Discovery and Development

WALTHAM, Mass., June 19 /PRNewswire-FirstCall/ -- Thermo Fisher Scientific Inc. , the world leader in serving science, has opened a new RNAi Discovery and Therapeutic Services laboratory at its RNAi research and production center in Lafayette, Colorado, USA. The new laboratory offers advanced RNAi (RNA-interference) screening and analysis services, as well as development of new therapeutic technologies involving RNAi.

"We have an industry-leading position in RNA- and RNAi-based technologies through our Dharmacon product line, now marketed under the Thermo Scientific brand," said Marc N. Casper, executive vice president of Thermo Fisher Scientific. "Our core expertise in RNAi biology and therapeutic technology development, high-throughput screening, RNA chemistry and drug discovery research, combined with our unique portfolio of bioreagents, instrument systems and robotics, enables us to perform highly advanced contract services in-house. We can also offer customers the option of transferring this integrated workflow to their own facilities."

The RNAi Discovery and Therapeutic Services laboratory features a highly integrated platform of Thermo Scientific technologies, including Dharmacon siRNA and miRNA libraries, BioImage and Cellomics high-content screening reagents and image analysis instrumentation, as well as robotics and software for laboratory automation.

"By providing RNAi-based screening on a contract basis, we will make it possible for any laboratory to realize the benefits of this important advancement in drug discovery," added Casper. "The RNAi Discovery and Therapeutic Services laboratory provides clients with access to unmatched scientific expertise and the ability to rapidly achieve meaningful results from this innovative workflow, while providing training and systems recommendations to clients establishing their own internal capabilities."

The RNAi contract services support researchers in pharmaceutical, biotechnology and academic fields by providing critical drug-discovery activities including target identification, target validation, biomarker discovery and RNAi therapeutic technology development. The laboratory will also provide supplemental resources and expertise for overburdened labs already using RNAi technology. Services range from a single screen to multi- component projects, and include RNAi-based high-throughput screening and hit validation, high-content screening, microRNA expression profiling and analysis, as well as lab automation and integration. Therapeutic discovery and technology development is also available for clients pursuing RNAi-based therapeutics.

For more information, please contact Dharmacon.rnai_services@thermofisher.com or visit http://www.thermo.com/dharmacon.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With an annual revenue rate of more than $9 billion, we employ 30,000 people and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit http://www.thermofisher.com/.

The following constitutes a "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward- looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the company's most recent Quarterly Report on Form 10-Q under the caption "Risk Factors," which is on file with the Securities and Exchange Commission and available in the "Investors" section of our Website under the heading "SEC Filings." We also may make forward-looking statements about the benefits of the merger of Thermo Electron and Fisher Scientific, including statements about future financial and operating results, the new company's plans, objectives, expectations and intentions and other statements that are not historical facts. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the risk that the businesses will not be integrated successfully; the risk that the cost savings and any other synergies from the transaction may not be fully realized or may take longer to realize than expected; disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers; competition and its effect on pricing, spending, third-party relationships and revenues; the need to develop new products and adapt to significant technological change; implementation of strategies for improving internal growth; use and protection of intellectual property; dependence on customers' capital spending policies and government funding policies; realization of potential future savings from new productivity initiatives; general worldwide economic conditions and related uncertainties; the effect of changes in governmental regulations; the effect of exchange rate fluctuations on international operations; the effect of laws and regulations governing government contracts; the effect of competing with certain of our customers and suppliers; and the effect of rapid changes in the healthcare industry. While we may elect to update forward- looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.

Media Contact Information: Lori Gorski Phone: 781-622-1242 Email: lori.gorski@thermofisher.com Website: http://www.thermofisher.com/ Investor Contact Information Ken Apicerno Phone: 781-622-1111 Email: ken.apicerno@thermofisher.com